Regenxbio (RGNX) Cash from Financing Activities (2014 - 2025)

Regenxbio's Cash from Financing Activities history runs 12 years deep, the most recent figure standing at -$9.6 million for Q4 2025.

• On a quarterly basis, Cash from Financing Activities fell 23.82% year-over-year to -$9.6 million in Q4 2025; TTM through Dec 2025 was $116.8 million, a 25.99% increase from a year earlier, with the FY2025 full-year figure at $116.8 million, up 25.99% from the prior year.
• Cash from Financing Activities fell to -$9.6 million in Q4 2025 per RGNX's latest filing, from -$7.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $211.3 million in Q1 2021 and bottomed at -$12.0 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is -$7.3 million (2021), against an average of $17.0 million.
• Biggest YoY gain for Cash from Financing Activities was 7552.52% in 2021; the steepest drop was 436.27% in 2021.
• Year by year, Cash from Financing Activities stood at -$7.6 million in 2021, then declined by 17.12% to -$8.9 million in 2022, then plunged by 34.1% to -$12.0 million in 2023, then surged by 35.3% to -$7.7 million in 2024, then dropped by 23.82% to -$9.6 million in 2025.
• Per Business Quant, the three latest RGNX Cash from Financing Activities figures stand at -$9.6 million (Q4 2025), -$7.1 million (Q3 2025), and $139.2 million (Q2 2025).